Table 2

Phase III placebo-controlled trials assessing maintenance strategies with single-agent poly (ADP-ribose) polymerase inhibitors (PARPi) after response to platinum-based chemotherapy. Additionally, the three trials in platinum-sensitive settings included patients with ≥2 lines of platinum therapy.

Trial/PARPiHistologyBRCA mutationHRD, excluding BRCA (assay)Residual diseaseCA125 level
Front-Line – Switch Maintenance
SOLO1
Olaparib
HGS 96%
HGE 2%
Mixed 2%
Germline 99%
Somatic 1%
N/AN/ANo rising
PRIMA
Niraparib
HGS 95%
HGE 3%
Mixed 2%
Germline or somatic 30%HRD 20%
(Myriad Mychoice cut-off: ≥42%)
≤2 cmNormal or 90% ↓ with chemotherapy
Front-Line – Continuation Maintenance in Three-Arm Design
VELIA
Veliparib
HGS 100%Germline 19%
Somatic 7%
HRD 29% (Myriad Mychoice cut-off: ≥33%)N/A__
Platinum-Sensitive Recurrence – Switch Maintenance (PARPi-Naïve)
SOLO2
Olaparib
HGS 91%
HGE 6%
Mixed 3%
Germline 97%
Somatic 0%
N/AN/ANo rising
NOVA
Niraparib
Predominantly HGS*Germline 37%
Somatic 8%
HRD 29%
(Myriad Mychoice cut-off: ≥42%)
≤2 cmNormal or 90% ↓ with chemotherapy
ARIEL3
Rucaparib
HGS 95%
HGE 4%
Mixed 1%
Germline or somatic 35%LOH high 28%
(Foundation medicine T5 cut-off: ≥16%)
N/ANormal
  • *Non-HGS with gBRCAm were also eligible. Number of patients with other histologies has not been reported.

  • HGE, high-grade endometrioid; HGS, high-grade serous; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; mixed, HGS and HGE; N/A, not applicable; PARPi, poly (ADP-ribose) polymerase inhibitor.